Search research articles
Contact Us
Filters
Showing results (361-370 of 384) with videos related to
Page
of 39
Sort By:
Journal of Biological Regulators and Homeostatic Agents
|
May 11, 2002
Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report
B Capiluppi, A Saracco, N Gianotti, et al.
Journal of Biological Regulators and Homeostatic Agents
|
April 14, 2000
Four drug-HAART in primary HIV-1 infection: clinical benefits and virologic parameters
B Capiluppi, D Ciuffreda, G P Quinzan, et al.
The Journal of Experimental Medicine
|
August 4, 1997
Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele
L Furci, G Scarlatti, S Burastero, et al.
AIDS (London, England)
|
December 12, 2001
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine
F W Wit, R Wood, A Horban, et al.
Infection
|
May 28, 2009
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts
C Torti, G Lapadula, A Antinori, et al.
European Journal of Immunology
|
February 17, 1998
Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort
R A Morawetz, G P Rizzardi, D Glauser, et al.
The Journal of Infectious Diseases
|
July 7, 2000
Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection
A Brambilla, C Villa, G Rizzardi, et al.
The Journal of Clinical Investigation
|
March 23, 2000
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA
G P Rizzardi, R J De Boer, S Hoover, et al.
Antimicrobial Agents and Chemotherapy
|
October 19, 2000
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group
V Joly, M Moroni, E Concia, et al.
AIDS Research and Human Retroviruses
|
January 12, 2001
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
R Bures, A Gaitan, T Zhu, et al.
Page
of 39
Search research articles
Search
Showing results (361-370 of 384) with videos related to
Sort By:
Page
of 39
Journal of Biological Regulators and Homeostatic Agents
|
May 11, 2002
Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report
B Capiluppi, A Saracco, N Gianotti, et al.
Journal of Biological Regulators and Homeostatic Agents
|
April 14, 2000
Four drug-HAART in primary HIV-1 infection: clinical benefits and virologic parameters
B Capiluppi, D Ciuffreda, G P Quinzan, et al.
The Journal of Experimental Medicine
|
August 4, 1997
Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele
L Furci, G Scarlatti, S Burastero, et al.
AIDS (London, England)
|
December 12, 2001
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine
F W Wit, R Wood, A Horban, et al.
Infection
|
May 28, 2009
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts
C Torti, G Lapadula, A Antinori, et al.
European Journal of Immunology
|
February 17, 1998
Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort
R A Morawetz, G P Rizzardi, D Glauser, et al.
The Journal of Infectious Diseases
|
July 7, 2000
Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection
A Brambilla, C Villa, G Rizzardi, et al.
The Journal of Clinical Investigation
|
March 23, 2000
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA
G P Rizzardi, R J De Boer, S Hoover, et al.
Antimicrobial Agents and Chemotherapy
|
October 19, 2000
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group
V Joly, M Moroni, E Concia, et al.
AIDS Research and Human Retroviruses
|
January 12, 2001
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
R Bures, A Gaitan, T Zhu, et al.
Page
of 39